Oncotelic Therapeutics, Inc.
OTLC
$0.09
$0.000.54%
OTC PK
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 646.58% | -34.82% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 643.94% | -34.72% | |||
| Operating Income | -643.94% | 34.72% | |||
| Income Before Tax | -629.66% | 157.75% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -629.66% | 157.75% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -0.59% | 2.90% | |||
| Net Income | -476.90% | 193.04% | |||
| EBIT | -643.94% | 34.72% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -457.14% | 200.00% | |||
| Normalized Basic EPS | -400.00% | 225.00% | |||
| EPS Diluted | -516.67% | 185.71% | |||
| Normalized Diluted EPS | -475.00% | 200.00% | |||
| Average Basic Shares Outstanding | 4.44% | 0.21% | |||
| Average Diluted Shares Outstanding | -5.82% | 11.14% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||